Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 23.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7Q9 ISIN: BE0974260896 Ticker-Symbol: 1C0 
Frankfurt
23.10.19
08:09 Uhr
7,590 Euro
-0,740
-8,88 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELYAD SA Chart 1 Jahr
5-Tage-Chart
CELYAD SA 5-Tage-Chart
RealtimeGeldBriefZeit
7,840
8,000
11:43

Aktuelle News zur CELYAD Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.10.Celyad Announces October and November 2019 Investor Conference Schedule345Regulatory News: Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
► Artikel lesen
02.10.CELYAD S.A. - 6-K, Report of foreign issuer-
Börsennews zur CELYAD Aktie und weiteren Hot Stocks erhalten
02.10.Celyad SA: Celyad Announces October and November 2019 Investor Conference Schedule-
02.10.Celyad SA: Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting-
02.10.Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting236Poster presentations to highlight allogeneic and autologous NKG2D-based CAR-T therapies for the treatment of advanced metastatic colorectal (mCRC) cancers Regulatory News: Celyad (Brussels:CYAD)...
► Artikel lesen
16.09.Celyad SA: Celyad Announces Closing of $20 Million Global Offering-
16.09.Celyad closes $20M capital raise3
16.09.Celyad Announces Closing of $20 Million Global Offering344Regulatory News: Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
► Artikel lesen
12.09.CELYAD S.A. - 6-K, Report of foreign issuer1
12.09.XFRA 1C0: WIEDERAUFNAHME/RESUMPTION165FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT...
► Artikel lesen
12.09.Celyad Announces Pricing of $20.0 Million Global Offering303Regulatory News: Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the pricing...
► Artikel lesen
12.09.Celyad down 24% on equity offering5
12.09.Celyad SA: Celyad Announces Pricing of $20.0 Million Global Offering2
11.09.The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway20
11.09.XFRA 1C0: AUSSETZUNG/SUSPENSION155DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CELYAD S.A. 1C0...
► Artikel lesen
11.09.Celyad offering up to 2M shares7
10.09.Celyad SA: Celyad Announces Launch of Proposed Global Offering1
10.09.Celyad Announces Launch of Proposed Global Offering232Regulatory News: Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it...
► Artikel lesen
10.09.Be The Match BioTherapies and Celyad Announce Collaboration to Advance Development of Allogeneic CAR-T Therapies220Alliance will support the clinical progression of Celyad's non-gene edited allogeneic CAR-T candidates Be The Match BioTherapies, an organization offering solutions for companies developing and...
► Artikel lesen
04.09.Celyad Successfully Produces CYAD-01 with OptimAb Mfg. Process-
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2